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Abstract  Hepatitis  E  is  an  inﬂammatory  liver  disease  caused  by  hepatitis  E  virus  (HEV)  infec-
tion, which  is  endemic  in  China,  India,  Nepal,  and  in  several  Asian  and  African  countries,  where
the prevalence  can  be  as  high  as  50%.  In  non-endemic  countries,  an  increasing  number  of
non-travel  associated  HEV  has  been  reported  in  recent  years,  particularly  in  Europe.
The authors  describe  the  clinical  case  of  a  puerperal  24-year-old  woman  from  Pakistan  admit-
ted to  our  Tertiary  Care  Medical  Center  with  acute  hepatic  failure  developed  during  the  third
trimester of  her  pregnancy.  She  was  icteric  with  grade  III  encephalopathy  and  hypothermia.
Laboratory  values  showed  signiﬁcant  AST,  ALT  and  LDH  elevations  of  twelve  times  the  upper
normal limit,  and  total  bilirubin  was  signiﬁcantly  elevated  (41.20  mg/dL).  Prothrombin  time  was
prolonged (4  s)  and  factor  V  activity  was  diminished  (15.1%).  Extracorporeal  albumin  dialysis
was initiated,  but  clinical  deterioration  occurred  within  48  h,  so  she  underwent  OLT  at  day  4
post-admission.
Severe forms  of  HEV  are  known  to  be  more  pronounced  in  pregnant  women.  Even  though
most of  the  described  cases  of  acute  hepatic  failure  associated  to  HEV  during  pregnancy  had
a favorable  clinical  course,  some  cases  of  fulminant  liver  failure  and  death  are  described.  It  is
unknown whether  liver  transplant  outcomes  in  this  setting  are  different  from  other  causes  of
acute liver  failure.  To  our  knowledge,  this  is  the  ﬁrst  case  report  in  Portugal  from  a  pregnantatic  failure  due  to  fulminant  hepatitis  E  that  underwent  successfulwoman who  developed  hep
liver transplantation.
©  2012  Sociedade  Portuguesa  de  Gastrenterologia  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Gravidez
Hepatite  E  fulminante  numa  mulher  grávida
Resumo  A  Hepatite  E  é  uma  doenc¸a  inﬂamatória  do  fígado  causada  pelo  Vírus  da  Hepatite  E
(VHE). Este  vírus  é  endémico  na  China,  Nepal,  Índia  e  em  vários  países  Africanos  e  Asiáticos,
onde a  sua  prevalência  pode  atingir  os  50%.  Em  países  não  endémicos,  particularmente  na
Europa, tem-se  veriﬁcado  um  aumento  da  prevalência  de  VHE  não  associada  a  viagens.
Os autores  descrevem  o  caso  de  uma  doente  de  24  anos,  puérpera,  natural  do  Paquistão,
admitida no  nosso  Centro  Terciário  com  insuﬁciência  hepática  aguda,  com  início  no  terceiro
trimestre  da  gravidez.  A  doente  encontrava-se  ictérica,  com  encefalopatia  hepática  grau  III
e hipotermia.  Os  valores  laboratoriais  mostraram  elevac¸ão  signiﬁcativa  de  12  vezes  o  limite
superior do  normal  das  aminotransferases  (AST  e  ALT)  e  da  LDH,  com  bilirrubina  total  elevada
(41.2 mg/dL),  prolongamento  do  tempo  de  protrombina  (4  seg)  e  actividade  do  factor  V  dimin-
uída (15.1%).  A  doente  iniciou  diálise  de  albumina  extra-corporal,  contudo  veriﬁcou-se  rápida
deteriorac¸ão, tendo  sido  submetida  a  transplante  hepático  no  4◦ dia  após  a  admissão.
Formas mais  graves  de  hepatite  associada  a  VEH  têm  sido  descritas  durante  a  gravidez.  Geral-
mente, mesmo  as  formas  mais  graves  têm  uma  evoluc¸ão  tendencionalmente  favorável,  com
apenas alguns  casos  descritos  de  morte  e  de  hepatite  fulminante.  Desconhece-se  para  já  qual
o resultado  a  longo  prazo  dos  doentes  transplantados  por  hepatite  E  fulminante,  quando  com-
parados  com  outras  populac¸ões.  Este  caso  representa  o  primeiro  caso  descrito  em  Portugal
de uma  doente  grávida  com  hepatite  fulminante  causada  por  VHE,  submetida  com  sucesso  a
transplante  hepático.
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Introduction
Hepatitis  E  is  an  inﬂammatory  liver  disease  caused  by  hep-
atitis  E  virus  (HEV)  infection,  which  is  a  single-stranded,
non-enveloped  RNA  virus  and  the  only  virus  within  the  genus
Hepevirus  and  the  family  Hepeviridae.1,2 The  ﬁrst  described
cases  of  acute  liver  disease  caused  by  an  enteric  infectious
agent  that  differed  from  hepatitis  A  and  hepatitis  B  viruses
were  reported  in  India  in  the  1970s.2 HEV  is  endemic  in
China,  India,  Nepal,  as  well  as  in  several  Asian  and  African
countries,  where  the  prevalence  of  HEV  IgG  antibody  can  be
as  high  as  50%.3 It  has  been  recently  estimated  that  its  infec-
tion  causes  more  than  3  million  symptomatic  cases  of  acute
hepatitis  E  each  year,  resulting  in  approximately  70,000
deaths  worldwide.4 In  non-endemic  countries,  an  increas-
ing  number  of  non-travel  associated  HEV  cases  have  been
reported  in  recent  years,  particularly  in  Europe.5,6 In  Portu-
gal,  sporadic  cases  have  been  reported,  and  a  study  on  237
individuals,  from  which  152  were  patients  from  a  Gastroen-
terology  Department,  showed  that  4.2%  of  the  population
enrolled  was  seropositive  for  anti-HEV.  Furthermore,  in  the
seropositive  group,  only  20%  had  a  history  of  traveling  to
endemic  countries.7
Testing  for  hepatitis  E  should  be  done  in  the  diagnos-
tic  analysis  of  all  patients  with  acute  or  chronic  hepatitis
that  cannot  be  explained  by  other  causes.  Acute  HEV  infec-
tion  is  diagnosed  in  immunocompetent  individuals  based  on
the  detection  of  anti-HEV  IgM.  Immunocompromised  indi-
viduals  should  always  be  tested  for  HEV  RNA,  if  there  is
suspicion  that  they  are  infected,  because  seroconversion  can
be  delayed  in  these  patients.8,9
Most  infections  have  a  clinically  silent  course.  In  symp-
tomatic  cases,  the  incubation  period  ranges  from  2  to
8  weeks,  with  a  mean  of  40  days.1 Initial  symptoms  of
acute  hepatitis  E  are  typically  unspeciﬁc  and  include  ﬂu-like
myalgia,  arthralgia,  weakness  and  vomiting.  However,  more
c
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evere  forms  of  acute  liver  disease  can  occur  in  pregnant
omen  or  patients  with  underlying  chronic  liver  diseases,
ometimes  progressing  to  fulminant  hepatic  failure.10 In
mmunocompetent  patients,  HEV  is  mainly  self-limited  and
auses  no  chronic  evolution.  In  fact,  in  these  individ-
als,  acute  hepatitis  E  does  not  usually  require  therapy.11
evertheless,  in  immunocompromised  patients,  HEV  can
ursue  a  chronic  course.  Persistent  HEV  infection  was  ﬁrst
eported  in  2008  in  8  French  solid  organ  transplant  recipients
n  immunosuppression.  Furthermore,  one  kidney-transplant
atient  had  cirrhosis  attributed  to  chronic  HEV  infection.2
EV-associated  liver  cirrhosis  or  hepatocellular  carcinoma
n  the  immunocompetent  patient  has  not  been  reported,  so
ar;  however,  acute  HEV  infection  is  known  to  be  a cause  of
ecompensated  liver  cirrhosis.12
ase report
 24-year-old  puerperal  woman  was  admitted  to  our  Ter-
iary  Care  Medical  Center  with  acute  hepatic  failure.  She
as  a Pakistani  woman  living  in  Portugal  for  3  years  that
ad  recently  traveled  to  Pakistan  while  pregnant,  for  a  total
tay  of  3  months.  She  returned  to  Portugal  during  the  third
rimester  of  her  pregnancy,  3  weeks  before  admission  in  our
ospital.  During  her  time  in  Pakistan,  she  was  observed  by
n  Obstetrician  and  did  a  fetal  ultrasound  that  she  reported
s  being  normal.  She  denied  having  any  symptoms  while  in
akistan,  contact  with  sick  people  and/or  previous  history
f  hepatitis  in  her  relatives.  Her  background  was  unremark-
ble,  she  was  married  and  mother  of  a  2-year-old  healthy
hild,  with  a regular  pregnancy  and  an  eutocic  delivery  and
 history  of  2  previous  spontaneous  abortions.  She  denied
urrent  medication  and  toxic  or  alcohol  consumption.
During  pregnancy  week  32,  the  patient  reported  nausea,
omiting,  asthenia  and  myalgia.  She  went  to  an  outpa-
ient  Obstetrics  Consult  in  another  Institution  and  in  the
2 M.  Velosa  et  al.
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Figure  1  Extensive  areas  of  conﬂuent  necrosis  and  pseudo-
rosettes  formation  (H&E  50×).
Figure  2  Marked  hepatic  necrosis  with  regenerative  pseudo-
rosette formation.  There  is  cholestasis  and  moderate  mixed
inﬂammatory  inﬁltrate  (H&E  400×).12  
ame  day  was  referred  to  the  emergency  room,  because
he  also  had  jaundice.  She  did  not  recall  what  happened
ext.  At  that  point,  blood  tests  showed  high  liver  enzymes
transaminases  aspartate  transaminase  [ALT]  and  alanine
ransaminase  [ALT])  and  hyperbilirubinemia.  Labor  was
nduced  and  she  delivered  a  healthy  female  baby.  During  the
ext  12  h,  she  developed  grade  I  encephalopathy,  therefore
eing  transferred  to  the  ICU  of  our  hospital.  Upon  admis-
ion,  examination  showed  that  she  was  markedly  icteric,
ith  grade  III  encephalopathy  (Glasgow  Coma  Scale:  6).  She
as  hypothermic  (34.7 ◦C),  hemodynamically  stable,  with-
ut  palpable  hepatomegaly,  and  her  uterus  was  palpable
 cm  above  her  pubic  symphysis.  Laboratory  values  upon
dmission  showed  signiﬁcant  elevations  in  AST  (406  IU/L
normal,  10--37  UI/L]),  ALT  (569  IU/L  [normal,  10--37  UI/L]),
actate  dehydrogenase  (1358  [normal,  205--423  UI/L]),  alka-
ine  phosphatase  354  UI/L  [normal,  44--155  UI/L]  and  NH3  47
[normal,  8--33  mol/L]).  Bilirubin  was  signiﬁcantly  elevated
41.20  mg/dL,  [normal,  0.4--1.2  mg/dL]),  with  unconjugated
ilirubin  of  10.6  mg/dL.  Gamma-glutamyl  transpeptidase
GGT)  was  slightly  elevated  (63  UI/L  [normal,  10--49  UI/L]).
rterial  lactic  acid  was  elevated  (34  mg/dL  [normal,
.5--14.4  mg/dL]).  Prothrombin  time  was  prolonged  (PT-INR,
.4  [normal,  0.81--1.38]),  and  factor  V activity  was  dimin-
shed  (15.1%).  She  had  a  normal  platelet  count.  The  head
T  scan  was  normal  and  the  abdominal  ultrasound  showed
ormal  liver  echogenicity  without  structural  abnormali-
ies,  with  patent,  non-occluded  liver  vasculature.  Screening
or  hepatitis  A,  B,  C  and  G,  syphilis,  cytomegalovirus,
erpes  simplex  virus,  toxoplasmosis,  leptospirosis,  antin-
clear  antibodies  (ANA),  smooth  muscle  antibodies  (SMA)
nd  antibodies  to  liver/kidney  microsome  type  1  (LKM1)
ere  negative.  PCR  for  Hepatitis  E  RNA  was  strongly  pos-
tive,  so  she  was  diagnosed  with  acute  hepatic  failure
aused  by  acute  hepatitis  E,  with  hepatic  encephalopathy.
he  was  listed  for  urgent  orthotopic  liver  transplanta-
ion  (OLT)  and  immediately  started  on  extracorporeal
lbumin  dialysis  (Prometheus®),  but  clinical  deterioration
ccurred  within  48  h  Given  her  low  Glasgow  Coma  Scale
f  3,  mechanical  ventilation  was  required.  She  under-
ent  OLT  at  day  4  post-admission.  Her  explant  had  no
ajor  macroscopic  alterations,  except  a  slight  softening
f  its  consistency.  The  histological  analysis  revealed  exten-
ive  areas  of  conﬂuent  panlobular,  non-zonal  necrosis,
ith  porto-portal,  porto-central  and  centro-central  bridges.
he  residual  parenchyma  showed  ballooned  hepatocytes,
arked  pseudo-rosettes  formation  and  cholestasis,  either
ytoplasmatic  or  in  the  center  of  the  rosettes  (cholestatic
osettes).  Lobular  inﬂammation  with  lymphocytes,  plas-
ocytes,  some  neutrophils  and  numerous  histiocytes  were
lso  detected  (Figs.  1--3).  Immediate  graft  function  post-
ransplant  was  good  and  she  had  an  unremarkable  recovery.
erum  Hepatitis  E  RNA  (PCR)  was  negative  2  months  after
ransplantation.
Genotype  analysis,  performed  in  collaboration  between
olecular  Diagnostic  Section,  Clinical  Microbiology  &  Public
ealth  Laboratory  Addenbrooke’s  Hospital  (Cambridge),  UK
eference  Laboratory  and  Microbiology  Department,  Medi-
al  Sciences  University  (Lisbon)  conﬁrmed  that  the  virus  is
EV.  However,  maximal  similarity  with  more  than  one  geno-
ype  was  observed,  meaning  that  this  HEV  could  be  a  new
enotype.
o
a
eFigure  3  Hepatocyte  ballooning  (H&E  400×).
The  newborn  was  icteric  at  birth,  with  total  bilirubin
f  14.8  mg/dL  and  positive  IgG  anti-HEV  and  negative  IgM
nti-HVE.  She  underwent  phototherapy  treatment,  plus  one
xchange  transfusion,  with  normalization  of  total  bilirubin.
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study  received  sufﬁcient  information  and  gave  their  writtenFulminant  hepatitis  E  
After  3  weeks  at  the  neonatal  ICU,  she  was  transferred  to
the  Pediatric  Department,  where  she  was  released  after  7
weeks.
Discussion
In  a  general  population  living  in  a  country  where  HEV  is
endemic,  mortality  associated  with  fulminant  hepatitis  is
approximately  1%.5 These  severe  forms  of  HEV  are  more  pro-
nounced  in  pregnant  women,  in  which  mortality  can  be  as
high  as  20--30%.13
There  is  a  complex  interaction  among  viral,  host,
immunological  and  hormonal  factors,  producing  a  paradigm
of  severe  liver  damage  in  pregnancy.  The  maternal  immune
system  is  clearly  altered  to  tolerate  a  genetically  different
fetus.14 These  immunological  changes  promote  the  mainte-
nance  of  the  antigenic  fetus  in  the  maternal  environment  by
suppression  of  T-cell-mediated  immunity.  There  is  a  clear
shift  in  the  T-helper  type  1  (Th1):  Th2  cell  paradigm  dur-
ing  pregnancy,  with  a  deﬁnite  skew  toward  Th2  cells.  The
levels  of  most  cytokines  are  depressed,  particularly  during
the  initial  20  weeks  of  pregnancy.  CD4  counts  are  generally
lower  in  HEV  positive  pregnant  patients,  while  CD8  counts
are  higher.  The  ratio  of  CD4/CD8  in  these  patients  with
fulminant  hepatic  failure  was  signiﬁcantly  lower  when  com-
pared  to  HEV  negative  patients  or  controls.15 Viral  load  and
genotypes  have  been  implicated  in  the  severity  of  liver  dis-
ease,  and  HEV  viral  load  was  found  to  be  signiﬁcantly  higher
in  pregnant  when  compared  to  the  non-pregnant.16 Geno-
type  1  and  4  are  the  most  common  subtype  causing  HEV
infection  in  endemic  countries  as  Pakistan,  while  genotype
3  predominates  in  the  US.  The  genotype  of  this  patient  is
not  available  yet,  and  even  though  there  is  some  specu-
lation  regarding  the  inﬂuence  of  the  genotype  on  clinical
features  in  this  setting,  that  remains  to  be  proven.16 Fur-
thermore,  there  are  evidences  indicating  that  higher  steroid
hormone  levels,  as  presented  during  pregnancy,  may  inﬂu-
ence  viral  replication.17 For  the  time  being,  although  there
is  no  consensus  on  how  to  treat  patients  with  HEV  infection
in  pregnancy,  early  delivery  of  the  fetus,  if  possible,  should
be  attempted,  to  prevent  maternal  mortality.17
Most  of  the  described  cases  of  acute  hepatic  failure  asso-
ciated  to  HEV  during  pregnancy  had  a  favorable  clinical
course,  but  patients  developing  fulminant  liver  failure  had
a  higher  mortality  rate.13,18--20 However,  a  study  by  Bhatia
et  al.  showed  that  once  fulminant  hepatitis  appears,  the
mortality  rate  might  be  similar  in  pregnant  women  with  hep-
atitis  E  and  in  those  with  other  causes  of  severe  liver  injury.10
However,  despite  this  ﬁnding,  the  higher  incidence  of  symp-
tomatic  disease  and  that  of  FHF  among  pregnant  women
exposed  to  and/or  infected  with  HEV  implies  that  the  overall
mortality  rate  among  pregnant  women  is  much  higher  than
non-pregnant  woman  and  men  during  outbreaks  of  hepatitis
E.21
Liver  transplant  is  considered  an  option,  but  it  is  unknown
whether  its  outcomes  in  this  setting  are  different  from
other  causes  of  acute  liver  failure.  Furthermore,  vertically
transmitted  HEV  infection  through  cord  blood  is  known  to
cause  acute  hepatitis  in  newborn  babies.  Khuroo  et  al.  stud-
ied  19  newborn  babies  born  to  HEV  infected  mothers  and
showed  that  78.9%  n  =  15  of  those  babies  had  evidence  of
i
R
d213
ertically  transmitted  HEV  infection  at  birth.  Seven  babies
ied  in  the  ﬁrst  week  after  birth  and  all  the  surviving
abies  had  self-limited  disease,  while  none  had  prolonged
iremia.22
As  the  majority  of  cases  are  self-limited,  liver  biopsy  is
ot  usually  performed,  so  the  histology  data  about  HEV  acute
epatitis  are  scarce.  However,  several  cases  of  acute  HEV  in
he  western  world  have  recently  been  diagnosed  with  histo-
ogical  analysis.23,25,26 Malcolm  et  al.  assessed  liver  histology
rom  patients  with  acute  HEV,  either  locally  acquired  or
mported  from  endemic  areas,  and  found  some  differences.
he  latter  leads  to  spotty  or  conﬂuent  necrosis,  portal  and
obular  inﬂammation,  ballooning  degeneration  of  hepato-
ytes,  intracytoplasmic  and  intracanalicular  cholestasis  and
epatocyte  pseudo-rosette  formation,  in  accordance  with
he  features  of  our  case.24 On  the  other  hand,  sporadic  cases
how  geographical  variation  of  the  portal  inﬂammatory  inﬁl-
rate,  with  polymorphs  at  the  periphery  and  interface,  while
ymphocytes  at  the  center,  perivenular  edema  with  hep-
tocyte  loss,  aggregates  of  lipofuscin-containing  Kupffer
ells,  necrosis  and  ﬁbrosis  of  zone  3  and  no  pseudo-rosette
ormation.23 However,  these  differences  are  not  clearly
eﬁned  and  both  forms  may  have  cholestatic  features.25
hese  aspects  are  clearly  different  from  chronic  HEV  infec-
ion  in  immunocompromised  individuals,  as  they  present  a
ense  lymphocytic  portal  inﬁltrate,  piecemeal  necrosis  and
brosis,  similar  to  cases  of  HCV.26
Agrawal  et  al.  compared  the  histology  of  fulminant  HEV
ith  fulminant  HBV  cases  and  found  that  interface  hep-
titis  was  signiﬁcantly  more  frequent  in  patients  with  HBV
han  in  those  with  HEV.  Although  not  reaching  statistical  sig-
iﬁcance,  ballooning,  pseudo-rosette  formation,  steatosis
nd  plasma  cells  were  more  prevalent  in  HEV.  The  pseudo-
osettes  (a  striking  feature  of  our  case)  are  uncommon  in  the
estern  cases  and  frequent  in  the  cases  in  endemic  areas.25
The  histological  aspects  of  our  case  are  similar  to  those
ound  by  Malcolm  et  al.  and  Agrawal  et  al.  in  endemic  areas,
hich  correlates  with  the  anamnesis.  Although  the  correct
iagnosis  is  a  serologic  one,  it  seems  there  are  some  his-
ological  aspects  that  can  give  a  clue  on  the  HEV  etiology,
nd  even  some  differences  in  the  endemic/sporadic  cases,
robably  reﬂecting  different  genotypes.24
As  far  as  we  know,  this  is  the  ﬁrst  case  report  in  Portugal
rom  a  pregnant  woman  who  developed  hepatic  failure  due
o  fulminant  hepatitis  E  that  underwent  a  successful  liver
ransplantation.
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